HomeNewsBusinessIndia and US should work together in areas of pandemic preparedness, clinical trials: Balram Bhargava

India and US should work together in areas of pandemic preparedness, clinical trials: Balram Bhargava

The Indian government is taking the opportunity to develop the health care system in every way.

October 06, 2021 / 22:43 IST
Story continues below Advertisement
(Representative image: Reuters)
(Representative image: Reuters)

India and the US should work together in areas of pandemic preparedness and bilateral clinical trials, said Balram Bhargava, Director-General of Indian Council of Medical Research.

Speaking at the India Ideas Summit, organised by United States India Business Council, Bhargava said that bilateral clinical trials will be more cost effective and that the two countries can work in areas of capacity building for health and non-communicable diseases.

Story continues below Advertisement

Commenting on the takeaways from the Covid-19 pandemic, Bhargava noted that the Indian government is taking the opportunity to develop the health care system in every way.

Bhargava further said the government is working very hard to tackle the pandemic. The country administered 920 million doses of vaccines and conducted 600 million COVID tests in 18 months.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show